Blimark C, Holmberg E, Mellqvist UH, Landgren O, Bjorkholm M, Hultcrantz M, et al. Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients. Haematologica. 2015;100:107–13.

Article  PubMed  PubMed Central  Google Scholar 

Sorrig R, Klausen TW, Salomo M, Vangsted A, Gimsing P. Risk factors for infections in newly diagnosed multiple myeloma patients: a Danish retrospective nationwide cohort study. Eur J Haematol. 2019;102:182–90.

Article  PubMed  Google Scholar 

Raje NS, Anaissie E, Kumar SK, Lonial S, Martin T, Gertz MA, et al. Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group. Lancet Haematol. 2022;9:e143–61.

Article  CAS  PubMed  Google Scholar 

Ho M, Zanwar S, Buadi FK, Ailawadhi S, Larsen J, Bergsagel L, et al. Risk factors for severe infection and mortality In patients with COVID-19 in patients with multiple myeloma and AL amyloidosis. Am J Hematol. 2023;98:49–55.

Article  CAS  PubMed  Google Scholar 

Chen M, Zhao Y, Xu C, Wang X, Zhang X, Mao B. Immunomodulatory drugs and the risk of serious infection in multiple myeloma: systematic review and meta-analysis of randomized and observational studies. Ann Hematol. 2018;97:925–44.

Article  CAS  PubMed  Google Scholar 

Basler M, Lauer C, Beck U, Groettrup M. The proteasome inhibitor bortezomib enhances the susceptibility to viral infection. J Immunol. 2009;183:6145–50.

Article  CAS  PubMed  Google Scholar 

Nahi H, Chrobok M, Gran C, Lund J, Gruber A, Gahrton G, et al. Infectious complications and NK cell depletion following daratumumab treatment of Multiple Myeloma. PLoS One. 2019;14:e0211927.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhou D, Wang Y, Cheng H, Zhu L, Chen W, Li H, et al. Factors associated with infection events after chimeric antigen receptor T-cell therapy for relapsed or refractory multiple myeloma. J Infect Chemother. 2023;29:179–85.

Ludwig H, Boccadoro M, Moreau P, San-Miguel J, Cavo M, Pawlyn C, et al. Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network. Leukemia. 2021;35:31–44.

Article  PubMed  Google Scholar 

Terpos E, Engelhardt M, Cook G, Gay F, Mateos MV, Ntanasis-Stathopoulos I, et al. Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN). Leukemia. 2020;34:2000–11.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Martinez-Lopez J, Hernandez-Ibarburu G, Alonso R, Sanchez-Pina JM, Zamanillo I, Lopez-Munoz N, et al. Impact of COVID-19 in patients with multiple myeloma based on a global data network. Blood Cancer J. 2021;11:198.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pagano L, Salmanton-Garcia J, Marchesi F, Busca A, Corradini P, Hoenigl M, et al. COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA). J Hematol Oncol. 2021;14:168.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Song Q, Bates B, Shao YR, Hsu FC, Liu F, Madhira V, et al. Risk and outcome of breakthrough COVID-19 infections in vaccinated patients with cancer: real-world evidence from the national COVID cohort collaborative. J Clin Oncol. 2022;40:1414–27.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of coronavirus disease 2019 in China. N. Engl J Med. 2020;382:1708–20.

Article  CAS  PubMed  Google Scholar 

Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497–506.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yousif E, Premraj S. A review of long COVID with a special focus on its cardiovascular manifestations. Cureus. 2022;14:e31933.

PubMed  PubMed Central  Google Scholar 

Patel UK, Mehta N, Patel A, Patel N, Ortiz JF, Khurana M, et al. Long-term neurological sequelae among severe COVID-19 patients: a systematic review and meta-analysis. Cureus. 2022;14:e29694.

PubMed  PubMed Central  Google Scholar 

Korompoki E, Gavriatopoulou M, Hicklen RS, Ntanasis-Stathopoulos I, Kastritis E, Fotiou D, et al. Epidemiology and organ specific sequelae of post-acute COVID19: a narrative review. J Infect. 2021;83:1–16.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Korompoki E, Gavriatopoulou M, Fotiou D, Ntanasis-Stathopoulos I, Dimopoulos MA, Terpos E. Late-onset hematological complications post COVID-19: an emerging medical problem for the hematologist. Am J Hematol. 2022;97:119–28.

Article  CAS  PubMed  Google Scholar 

Vijenthira A, Gong IY, Fox TA, Booth S, Cook G, Fattizzo B, et al. Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients. Blood. 2020;136:2881–92.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Passamonti F, Cattaneo C, Arcaini L, Bruna R, Cavo M, Merli F, et al. Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study. Lancet Haematol. 2020;7:e737–45.

Article  PubMed  PubMed Central  Google Scholar 

Kuderer NM, Choueiri TK, Shah DP, Shyr Y, Rubinstein SM, Rivera DR, et al. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet. 2020;395:1907–18.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lee LYW, Cazier JB, Starkey T, Briggs SEW, Arnold R, Bisht V, et al. COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study. Lancet Oncol. 2020;21:1309–16.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dai M, Liu D, Liu M, Zhou F, Li G, Chen Z, et al. Patients with cancer appear more vulnerable to SARS-CoV-2: a multicenter study during the COVID-19 outbreak. Cancer Disco. 2020;10:783–91.

Article  CAS  Google Scholar 

Fernandez-Cruz A, Puyuelo A, Nunez Martin-Buitrago L, Sanchez-Chica E, Diaz-Pedroche C, Ayala R, et al. Higher mortality of hospitalized haematologic patients with COVID-19 compared to non-haematologic is driven by thrombotic complications and development of ARDS: an age-matched cohorts study. Clin Infect Pr. 2022;13:100137.

Article  Google Scholar 

Girmenia C, Cavo M, Corso A, Di Raimondo F, Musto P, Offidani M, et al. Management of infectious risk of daratumumab therapy in multiple myeloma: a consensus-based position paper from an ad hoc Italian expert panel. Crit Rev Oncol Hematol. 2022;172:103623.

Article  PubMed  Google Scholar 

Cipkar C, Chen C, Trudel S. Antibodies and bispecifics for multiple myeloma: effective effector therapy. Hematol Am Soc Hematol Educ Program. 2022;2022:163–72.

Article  Google Scholar 

Sharma A, Bhatt NS, St Martin A, Abid MB, Bloomquist J, Chemaly RF, et al. Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort study. Lancet Haematol. 2021;8:e185–93.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hansen DK, Sidana S, Peres LC, Colin Leitzinger C, Shune L, Shrewsbury A, et al. Idecabtagene vicleucel for relapsed/refractory multiple myeloma: real-world experience from the myeloma CAR T consortium. J Clin Oncol. 2023;41:2087–97.

Article  CAS  PubMed  Google Scholar 

Rodriguez-Otero P, San-Miguel JF. Cellular therapy for multiple myeloma: what’s now and what’s next. Hematol Am Soc Hematol Educ Program. 2022;2022:180–9.

Article  Google Scholar 

Ludwig H, Sonneveld P, Facon T, San-Miguel J, Avet-Loiseau H, Mohty M, et al. COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network. Lancet Haematol. 2021;8:e934–46.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chuleerarux N, Manothummetha K, Moonla C, Sanguankeo A, Kates OS, Hirankarn N, et al. Immunogenicity of SARS-CoV-2 vaccines in patients with multiple myeloma: a systematic review and meta-analysis. Blood Adv. 2022;6:6198–207.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gagelmann N, Passamonti F, Wolschke C, Massoud R, Niederwieser C, Adjalle R, et al. Antibody response after vaccination against SARS-CoV-2 in adults with hematological malignancies: a systematic review and meta-analysis. Haematologica. 2022;107:1840–9.

Article  CAS  PubMed  Google Scholar 

Wang X, Sima L. Antibody response after vaccination against SARS-CoV-2 in adults with hematological malignancies: a systematic review and meta-analysis. J Infect. 2022;S0163-4453(22)00674-0. https://doi.org/10.1016/j.jinf.2022.11.013.

Mittelman M, Magen O, Barda N, Dagan N, Oster HS, Leader A, et al. Effectiveness of the BNT162b2mRNA COVID-19 vaccine in patients with hematological neoplasms in a nationwide mass vaccination setting. Blood. 2022;139:1439–51.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Goldwater MS, Stampfer SD, Sean Regidor B, Bujarski S, Jew S, Chen H, et al. Third dose of an mRNA COVID-19 vaccine for patients with multiple myeloma. Clin Infect Pr. 2023;17:100214.

Article  Google Scholar 

Hag